Romosozumab meets in Phase III osteoporosis study

Amgen Inc. (NASDAQ:AMGN) and partner UCB Group (Euronext:UCB) said romosozumab ( AMG 785) met the primary endpoint of the Phase III STRUCTURE trial to treat osteoporosis in postmenopausal women. The compound significantly increased hip bone mineral density from baseline at 12 months compared to Forteo teriparatide in patients previously treated with bisphosphonates.

Amgen said final results from the open-label, 436-patient trial will be presented at an upcoming meeting; Amgen spokesperson Kristen Davis declined to disclose a timeline. ...